Napoleone Ferrara, M.D. Awarded the 2023 Keio Medical Science Prize
|
Keio University in Tokyo, Japan’s oldest private university, annually awards the Keio Medical Science Prize to recognize researchers who have made outstanding contributions to the fields of medicine and the life sciences. The Keio is the only prize of its kind awarded by a Japanese university, and nine Keio recipients subsequently have been awarded Nobel Prizes. The 28th Keio Medical Science Prize has been awarded to Moores Member Napoleone Ferrara, M.D. and Kyoto University's Kazutoshi Mori, Ph.D. Read More»
|
Jill P. Mesirov, Ph.D. Awarded Breaking Barriers Award
|
Moores Member Dr. Jill Mesirov was awarded the Breaking Barriers Award, which honors women who have paved the way to inspire girls and women of all ages, at the World Tennis Association's WTA500 Cymbiotika San Diego Open on September 15, 2023. Dr. Mesirov was nominated for the award for her research in genomics (particularly the Human Genome Project), contributions to cancer genomics over the past 3 decades, and dedication to supporting women in science. Congratulations to Dr. Mesirov.
|
Moores Research Program Seminar Series Return
|
With the academic year beginning in just a few short weeks, Moores Research Administration would like to remind you that the various Moores research program seminar series will resume soon. View Announcement and Schedule»
|
|
|
September 20, 2023 | 12:00 p.m. to 1:00 p.m.
Moores Comer Commons
|
September 21, 2023 | 12:00 p.m. to 1:00 p.m.
Moores Comer Commons
|
September 26, 2023 | 12:00 p.m.
Leichtag Biomedical Research Building, Room 107
|
October 3, 2023 | 12:00 p.m.
Leichtag Biomedical Research Building, Room 107
|
|
|
CLINICAL TRIALS OFFICE (CTO) TRANSFORMATION INITIATIVE |
-
New positions will be posted soon for new career opportunities and pathways to specialize or take on leadership roles integral to the ongoing CTO transformation. These positions will provide opportunities for professional development that may align with your unique skillsets and interests. Be on the lookout for announcements.
-
The Disease Team Approval Form now reflects eligibility criteria for Fast Lane. Trials selected for Fast Lane will receive prioritization by a dedicated, cross-functional SWAT team to achieve accelerated activation timelines. Indeed, over the past 6 weeks, 36 trials have entered Fast Lane, and four have been activated across the Lung, Breast, and GU teams. Congratulations to the cross-functional teams who are prioritizing this important initiative. CTO will spotlight key players in an upcoming newsletter.
- Working groups for data and/or technology-related initiatives have been developed, and opportunities have been prioritized. Of the over 120 process improvement opportunities identified, those ranked as high priority have been assigned preliminary timelines and ownership, and execution is underway.
-
CTO encourages you to continue providing your feedback and insight, as it plays an essential role in the ongoing efforts to transform the CTO.
|
|
|
FEATURED FUNDING OPPORTUNITIES |
This mechanism provides support to develop and enhance collaborations and resources necessary for a network of organizations to rapidly execute either Phase II or Phase II-linked Phase I (Phase I/II) kidney cancer clinical trials. These trials feature investigations of high-impact, novel therapeutic agents or approaches for the management or treatment of kidney cancer. Applicants must demonstrate a broad understanding of kidney cancer research, which includes knowledge of the current state of clinical studies and priorities related to kidney cancer. Applicants are encouraged to familiarize themselves with the FY23 Overarching Strategic Goals and Focus Areas to prepare an application. Support from this mechanism is to be directed toward consortium infrastructure needs rather than direct support of the trials themselves.
Deadline: Thursday, October 26, 2023
|
MRA is pleased to announce an RFP for pre-clinical, translational, and early clinical research to produce high-impact, near-term advancements in melanoma prevention, detection, diagnosis, and treatment. Proposals must address a shortcoming in translational science (i.e., turning scientific discoveries into tools and/or treatments for high-risk individuals and patients with melanoma). Successful proposals will describe proposed research that applies important basic and preclinical discoveries to the near-term development of clinical trials and studies to improve melanoma detection, prevention, diagnosis, and/or treatment. Proposals for clinical studies to test well-defined and clearly articulated hypotheses are welcome and should be accompanied by a brief protocol synopsis and timeline that includes milestones. Eligibility and deadlines vary, depending on award type.
Deadline: Multiple—depending on award; see RFP for details.
|
For this NOFO, NCI encourages proposed projects that promote transformative discoveries in cancer biology and/or oncology through the use of nanotechnology. These projects should (1) overcome major barriers in cancer biology and/or oncology, using nanotechnology, and (2) feature mechanistic studies to expand the fundamental understanding of nanomaterial and/or nano-device interactions with biological systems. These studies must be relevant to either the delivery of nanoparticles and/or nano-devices to desired and intended cancer targets in vivo and/or characterization of detection and diagnostic devices and sensors in vitro. IRCN awards are expected to produce fundamental knowledge to aid future and more informed development of nanotechnology-based cancer interventions. The clinical translation of these interventions is beyond the scope of this NOFO.
Deadline: November 3, 2023; May 3, 2024; November 4, 2024; May 5, 2025
|
Tower Cancer Research Foundation supports forward thinking research work in Southern California. The Career Development award will support young investigators to continue their laboratory studies while improving their ability to secure further funding. The Tower scientific advisory board evaluates award proposals based on the following criteria: novelty of hypothesis; scientific quality; potential for revealing something meaningful about cancer; feasibility of the proposal; evidence of institutional support for the proposed project.
Deadline: November 6, 2023
|
|
|
Science
Rob Knight, Ph.D. (Structural and Functional Genomics)
|
Immunity
John T. Chang, M.D. (Cancer Biology and Signaling), Mitchell Kronenberg, Ph.D. (Hematologic Malignancies), Samuel A. Myers, Ph.D. (Cancer Biology and Signaling), and Hilde Cheroutre, Ph.D. (Cancer Biology and Signaling)
| Journal of Hepatology
Rohit Loomba, M.D. (Cancer Control Program)
|
|
|
NRG-GU012: Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)
|
PI: Tyler Seibert
NCT: NCT05327686
|
|
|
COMMUNITY OUTREACH AND ENGAGEMENT (COE) |
National Hispanic Heritage Month
|
Join COE in celebrating National Hispanic Heritage Month from September 15 to October 15, 2023. Below are events and webinars that are open to the entire community. COE looks forward to your participation!
|
- 9/21—Cervical Cancer Quality Improvement Learning Collaborative: Cervical Health on the Border
-
9/24—Linda Vista Health Fair with EWC, Access Microenterprise, COE, SD Family Care, and Asian Pacific Health Foundation
- 9/28—ACS Cancer Disparities Forum (Virtual)
- 10/4—Community Health and Resource Fair at the Jackie Robinson Family YMCA (Liver Cancer Awareness Month and Breast Cancer Awareness Month)
- 10/7—Community Outreach at Dia de la Mujer Festival
|
National Hispanic Heritage Month
|
COE is calling all Hispanic and Latine researchers to be featured on social media and in newsletters in honor of National Hispanic Heritage Month. If you would like to participate, then email Maritza Gomez at mag075@health.ucsd.edu and provide (1) your name, (2) your credentials, (3) one to two sentences about what you study/research, and (4) something meaningful to you about your Hispanic/Latine culture. COE looks forward to hearing from you.
|
Breast Cancer Screening Event at the San Diego American Indian Health Center
|
On Tuesday, September 12, 2023, COE facilitated a breast cancer screening event at the San Diego American Indian Health Center. Thirty individuals were screened during this collaborative effort with Alinea Health, sponsored by Bayer, and five were identified for diagnostic follow-up. COE extends its heartfelt gratitude to everyone who contributed to the success of this event. COE looks forward to providing an update on the next screening event set for Monday, September 18, 2023 at the Neighborhood Healthcare Clinic in El Cajon.
|
Cervical Cancer Quality Improved Learning Collaborative
|
Thursday, September 21, 2023 | 12:00 p.m.
|
COE will host its third session for the Cervical Cancer Quality Improved Learning Collaborative on Thursday, September 21, 2023 at 12:00 p.m. The featured presentation on cross-border collaborative efforts will be presented by Alicia Espinoza, M.P.H., Chief of Public Health Services Administration, Office of Border Health, County of San Diego, Health & Human Services Agency. Additional presentations will be announced soon. Eliminating the cervical cancer burden in our San Diego-Baja California border region will require all of us to work together.
If you are interested in learning more about this event, then please click the button below or contact COE at mcccoe@health.ucsd.edu. Thank you for helping to prevent cancer.
|
Community Market Health Fair
|
Sunday, September 24, 2023 | 10:00 a.m. to 2:00 p.m.
|
COE, along with Every Woman Counts, ACCESS, and the Asian Pacific Health Foundation, is excited to announce that it will be hosting a health fair on Sunday, September 24, 2023, from 10:00 a.m. to 2:00 p.m. This health fair will include not only various health screenings (e.g., blood pressure and cholesterol readings), but also cancer prevention education. This fair will be free and open to all who are interested. For more information, click the button below.
|
|
|
Manage your preferences | Opt Out using TrueRemove™
Got this as a forward? Sign up to receive our future emails.
View this email online.
|
3855 Health Sciences Drive MC 0698 | La Jolla, CA 92093 US
|
|
|
This email was sent to sjchristie@ucsd.edu.
To continue receiving our emails, add us to your address book.
|
|
|
|
